Investigational drug · Phase 3
IBI112
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Psoriasis.
Phase 3Last checked: Nov 19, 2026Latest source record: Dec 22, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
7
Any phase or sponsor naming "IBI112"
First trial start
2023
Oct 10, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IBI112", any sponsor or status.
Conditions studied
As listed on its trial records.
- Psoriasis
Approved drugs for the same conditions: Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "IBI112" as an intervention, largest first.
- IBI112 in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatmentPivotal-lookingCompleted
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT06049810 · 566 participants · Start Oct 10, 2023 · Primary completion Apr 29, 2025
Drug: IBI112; IBI112/placebo and 4 more · For: Psoriasis
Sites: Shanghai, China
- A Study to Evaluate IBI112 in the Treatment of Psoriasis With Moderate to Severe Plaque PsoriasisPivotal-lookingCompleted
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT05645627 · 500 participants · Start Feb 10, 2023 · Primary completion Aug 9, 2023
Drug: IBI112; placebo /IBI112 and 1 more · For: Psoriasis
Sites: Shanghai, China
- A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque PsoriasisPivotal-lookingCompleted
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT05003531 · 250 participants · Start Sep 23, 2021 · Primary completion Mar 25, 2022
Drug: IBI112 dose 2; IBI112 dose 4 and 3 more · For: Psoriasis
Sites: Beijing, China
- A Study of IBI112 in Chinese Patients With Psoriasis Who Were Previously Treated With BiologicsCompleted
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT05970978 · 152 participants · Start Aug 28, 2023 · Primary completion Jul 19, 2024
Drug: regular treatment; Intensive treatment · For: Psoriasis
Sites: Jinan, China
- A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative ColitisPivotal-lookingCompleted
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT05377580 · 150 participants · Start Jul 1, 2022 · Primary completion Jun 21, 2024
Drug: Period 1 IBI112 Placebo; Period 2 IBI112 dose 3 and 4 more · For: Ulcerative Colitis (UC)
Sites: Guangzhou, China
- A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque PsoriasisPivotal-lookingRecruiting
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.Industry
NCT07265284 · 104 participants (planned) · Start Dec 3, 2025 · Primary completion Sep 30, 2026
Drug: IBI112; placebo · For: Psoriasis
Sites: Beijing, China
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT04511624 · 46 participants · Start Aug 27, 2020 · Primary completion Jul 22, 2022
Drug: IBI112 dose1; IBI112 dose2 and 5 more · For: Healthy Subjects
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Safety and pharmacokinetics of IBI112, an IL-23 monoclonal antibody, in Chinese healthy volunteers: a first-in-human phase 1 study.
He J, Du W, Yang H, et al. · Expert Opin Investig Drugs 2023
- IBI112, a selective anti-IL23p19 monoclonal antibody, displays high efficacy in IL-23-induced psoriasiform dermatitis.
Li L, Wu Z, Wu M, et al. · Int Immunopharmacol 2020
Also in development for Psoriasis
- HSK44459Phase 39 trials
Haisco Pharmaceutical Group Co., Ltd. · Psoriasis, Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis
- TQH3906Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Psoriasis, Systemic Lupus Erythematosus, Psoriatic Arthritis
- AK111Phase 32 trials
Akeso · Psoriasis, Skin Diseases, Ankylosing Spondylitis
- Blinded EnvudeucitinibPhase 31 trial
Alumis Inc · Plaque Psoriasis, Psoriasis (PsO), Psoriasis
- CMAB015Phase 31 trial
Taizhou Mabtech Pharmaceutical Co.,Ltd · Psoriasis
- HPP737Phase 31 trial
Newsoara Biopharma Co., Ltd. · Psoriasis
- LZM012Phase 31 trial
Livzon Pharmaceutical Group Inc. · Psoriasis
- Open-Label EnvudeucitinibPhase 31 trial
Alumis Inc · Plaque Psoriasis, Psoriasis (PsO), Psoriasis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.